enGene Therapeutics Inc. (ENGN) stock: key figures, P/E, revenue and dividend
Health Care · ISIN US29286M1053
enGene Therapeutics Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -123.17 m USD |
| EBIT | -123.73 m USD |
| Net income | -117.30 m USD |
| Diluted EPS – continuing operations | 2.29 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About enGene Therapeutics Inc.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
More stocks
- 3billion (394800.KQ)
- Croghan Bancshares Inc (CHBH)
- KANGWON Co. Ltd (114190.KQ)
- Riber S.A (ALRIB.PA)
- Universal Token (UTKN)
- Kunyue Development Co Ltd (5206.TWO)
- MKH Oil Palm (East Kalimantan) Berhad (5319.KL)
- Westag (WUG.F)
- Shanghai Material Trading Co Ltd B (900927.SS)
- King Core Electronics Inc (6155.TW)
- MainStreet Bancshares, Inc. (MNSB)
- Hyundai Pharm (004310.KS)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.